Multiple Myeloma in 2020 and Beyond
Clinical experts from the US discuss global perspectives on current treatment strategies and emerging therapies, including MRD, IMiDs, proteasome inhibitors, and immunotherapy approaches.
Faculty Chair
Rafael Fonseca, MD
Washington Mayo Clinic, Phoenix, AZ, US
Faculty Members
Leif Bergsagel, MD
Mayo Clinic, Scottsdale, AZ, US
Irene Ghobrial, MD
Harvard Medical School, Dana-Farber Cancer Center, Boston, MA, US
Craig Hofmeister, MD, MPH
Emory University School of Medicine, Atlanta, GA, US
Andrzej Jakubowiak, MD, PhD
University of Chicago, IL, US
Sagar Lonial, MD, FACP
Emory University School of Medicine, Atlanta, GA, US
Tom Martin, MD
University of California San Francisco Medical Center, US
Keith Stewart, MB, ChB
University Health Network, Toronto, Canada
Peter Voorhees, MD
Levine Cancer Institute, Charlotte, NC, US
TOPICS COVERED IN THE REPORT
Clinical experts from the US discuss global perspectives on current treatment strategies and emerging therapies, including MRD, IMiDs, proteasome inhibitors, and immunotherapy approaches.
Download an example copy of the report for a full overview of the topics covered in the live virtual meeting and report. To secure your full copy of the report:
